<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Beyond Air Inc — News on 6ix</title>
    <link>https://6ix.com/company/beyond-air-inc</link>
    <description>Latest news and press releases for Beyond Air Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 20 Apr 2026 12:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/beyond-air-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835db4f78dffbe2df123d3d.webp</url>
      <title>Beyond Air Inc</title>
      <link>https://6ix.com/company/beyond-air-inc</link>
    </image>
    <item>
      <title>Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026</title>
      <link>https://6ix.com/company/beyond-air-inc/news/beyond-cancer-reports-updated-survival-and-safety-data-from-phase-1-uno-trial-presented-at-aacr-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/beyond-air-inc/news/beyond-cancer-reports-updated-survival-and-safety-data-from-phase-1-uno-trial-presented-at-aacr-2026</guid>
      <pubDate>Mon, 20 Apr 2026 12:00:00 GMT</pubDate>
      <description>Updated AACR poster data show continued survival follow-up in heavily pre‑treated patients following a single intratumoral UNO injection Received US patent allowance covering proprietary gas delivery technology for UNO GARDEN CITY, N.Y., April 20, 2026 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an investigational immunotherapeutic for solid tumors and subsidiary of Beyond Air, Inc. (NASDAQ: XAIR), toda</description>
    </item>
    <item>
      <title>Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)</title>
      <link>https://6ix.com/company/beyond-air-inc/news/beyond-air-expands-commercial-access-for-lungfitr-ph-through-a-purchasing-agreement-with-a-top-3-national-group-purchasing-organization-gpo-4</link>
      <guid isPermaLink="true">https://6ix.com/company/beyond-air-inc/news/beyond-air-expands-commercial-access-for-lungfitr-ph-through-a-purchasing-agreement-with-a-top-3-national-group-purchasing-organization-gpo-4</guid>
      <pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
      <description>GARDEN CITY, N.Y., April 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused</description>
    </item>
    <item>
      <title>Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO</title>
      <link>https://6ix.com/company/beyond-air-inc/news/beyond-air-inc-announces-resignation-of-steve-lisi-ceo-and-appointment-of-robert-goodman-chief-commercial-officer-as-ceo</link>
      <guid isPermaLink="true">https://6ix.com/company/beyond-air-inc/news/beyond-air-inc-announces-resignation-of-steve-lisi-ceo-and-appointment-of-robert-goodman-chief-commercial-officer-as-ceo</guid>
      <pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
      <description>New Leadership to Accelerate Market Adoption and Scale Commercial Growth GARDEN CITY, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR)</description>
    </item>
    <item>
      <title>Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial</title>
      <link>https://6ix.com/company/beyond-air-inc/news/beyond-cancer-reports-early-clinical-activity-and-favorable-safety-profile-with-interim-data-from-phase-1-uno-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/beyond-air-inc/news/beyond-cancer-reports-early-clinical-activity-and-favorable-safety-profile-with-interim-data-from-phase-1-uno-trial</guid>
      <pubDate>Tue, 17 Mar 2026 20:35:00 GMT</pubDate>
      <description>Data was published in the Online Itinerary Planner for the 2026 AACR Annual Meeting, and is scheduled to be presented at the meeting on April 19thGARDEN CITY, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an investigational immunotherapeutic for solid tumors and subsidiary of Beyond Air, Inc. (NASDAQ: XAIR), today announced early signs of clinical activity and a favorable safety and t</description>
    </item>
    <item>
      <title>Beyond Air to Participate in the 38th Annual Roth Conference in March</title>
      <link>https://6ix.com/company/beyond-air-inc/news/beyond-air-to-participate-in-the-38th-annual-roth-conference-in-march</link>
      <guid isPermaLink="true">https://6ix.com/company/beyond-air-inc/news/beyond-air-to-participate-in-the-38th-annual-roth-conference-in-march</guid>
      <pubDate>Wed, 11 Mar 2026 11:00:00 GMT</pubDate>
      <description>GARDEN CITY, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (&quot;Beyond Air&quot; or the &quot;Company&quot;), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman &amp; Chief Executive Officer of Beyond Air, will participate in the 38th Annual Roth Conference being held March 22nd to 24th in Laguna Niguel, CA. 38th Annual Roth ConferenceFormat:Fireside</description>
    </item>
    <item>
      <title>Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.</title>
      <link>https://6ix.com/company/beyond-air-inc/news/beyond-airr-announces-termination-of-agreement-to-sell-its-neuronos-subsidiary-to-xtl-biopharmaceuticals-ltd-3</link>
      <guid isPermaLink="true">https://6ix.com/company/beyond-air-inc/news/beyond-airr-announces-termination-of-agreement-to-sell-its-neuronos-subsidiary-to-xtl-biopharmaceuticals-ltd-3</guid>
      <pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
      <description>GARDEN CITY, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and</description>
    </item>
    <item>
      <title>Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections</title>
      <link>https://6ix.com/company/beyond-air-inc/news/beyond-airr-comments-on-landmark-independent-review-article-highlighting-the-antimicrobial-effects-of-high-dose-inhaled-nitric-oxide-and-its-therapeutic-potential-for-treating-respiratory-infections</link>
      <guid isPermaLink="true">https://6ix.com/company/beyond-air-inc/news/beyond-airr-comments-on-landmark-independent-review-article-highlighting-the-antimicrobial-effects-of-high-dose-inhaled-nitric-oxide-and-its-therapeutic-potential-for-treating-respiratory-infections</guid>
      <pubDate>Fri, 20 Feb 2026 13:00:00 GMT</pubDate>
      <description>GARDEN CITY, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today commented on the publication of an independent review article providing the most comprehensive overview to date of high‑dose inhaled nitric oxide (iNO) delivered at concentrations well above the FDA‑approved 20 ppm, and prese</description>
    </item>
    <item>
      <title>Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/beyond-air-inc/news/beyond-air-reports-fiscal-third-123000254</link>
      <guid isPermaLink="true">https://6ix.com/company/beyond-air-inc/news/beyond-air-reports-fiscal-third-123000254</guid>
      <pubDate>Fri, 13 Feb 2026 12:30:00 GMT</pubDate>
      <description>Increased revenue by 105% year-over-year (YoY) to $2.2 million in fiscal Q3 Maintain fiscal year 2026 revenue guidance of $8-10 million $22.3 million pro forma cash, cash equivalents, restricted cash and marketable securities, including net proceeds from recent PIPE transaction, expected to provide runway into calendar 2027 Signed binding letter of intent for XTL Biopharmaceuticals to acquire 85% of Beyond Air&apos;s subsidiary NeuroNOS; Beyond Air to receive up to $32.5 million from the combination</description>
    </item>
    <item>
      <title>Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026</title>
      <link>https://6ix.com/company/beyond-air-inc/news/beyond-cancer-abstract-featuring-phase-1-data-on-intratumoral-ultra-high-concentration-nitric-oxide-uno-in-solid-tumor-metastases-to-be-presented-at-the-aacr-annual-meeting-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/beyond-air-inc/news/beyond-cancer-abstract-featuring-phase-1-data-on-intratumoral-ultra-high-concentration-nitric-oxide-uno-in-solid-tumor-metastases-to-be-presented-at-the-aacr-annual-meeting-2026</guid>
      <pubDate>Wed, 04 Feb 2026 13:00:00 GMT</pubDate>
      <description>GARDEN CITY, N.Y., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors and subsidiary of Beyond Air, Inc. (NASDAQ: XAIR), today announced being selected to present an abstract featuring data from the Phase 1 trial of intratumoral UNO in solid tumor metastases at the American Association for Cancer Research (AACR) Annual Meeting 2026, which is scheduled to be h</description>
    </item>
    <item>
      <title>Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences</title>
      <link>https://6ix.com/company/beyond-air-inc/news/beyond-air-participate-two-upcoming-210500962</link>
      <guid isPermaLink="true">https://6ix.com/company/beyond-air-inc/news/beyond-air-participate-two-upcoming-210500962</guid>
      <pubDate>Tue, 27 Jan 2026 21:05:00 GMT</pubDate>
      <description>GARDEN CITY, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide to improve the lives of patients, today announced that Steve Lisi, Chairman &amp; Chief Executive Officer of Beyond Air, will participate in the 13th Annual BTIG MedTech, Digital Health, Life Science &amp; Diagnostic Tools Conference being held February 9th to 11th in Snowbird,</description>
    </item>
    <item>
      <title>Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast</title>
      <link>https://6ix.com/company/beyond-air-inc/news/beyond-air-schedules-third-fiscal-210500147</link>
      <guid isPermaLink="true">https://6ix.com/company/beyond-air-inc/news/beyond-air-schedules-third-fiscal-210500147</guid>
      <pubDate>Mon, 26 Jan 2026 21:05:00 GMT</pubDate>
      <description>GARDEN CITY, N.Y., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its third fiscal quarter ended December 31, 2025 on Friday, February 13, 2026. The Company&apos;s management team is scheduled to host a conference call and webcast at 8:00 am Ea</description>
    </item>
    <item>
      <title>Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules</title>
      <link>https://6ix.com/company/beyond-air-inc/news/beyond-air-announces-5-0-133000947</link>
      <guid isPermaLink="true">https://6ix.com/company/beyond-air-inc/news/beyond-air-announces-5-0-133000947</guid>
      <pubDate>Wed, 14 Jan 2026 13:30:00 GMT</pubDate>
      <description>GARDEN CITY, N.Y., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide to improve the lives of patients, today announced that it entered into a securities purchase agreement with an institutional investor to issue and sell, in a private placement priced at-the-market under Nasdaq rules, 3,930,818 shares of common stock (or pre-funded warra</description>
    </item>
    <item>
      <title>Beyond Air® Appoints Dan Moorhead as Chief Financial Officer</title>
      <link>https://6ix.com/company/beyond-air-inc/news/beyond-air-appoints-dan-moorhead-123000082</link>
      <guid isPermaLink="true">https://6ix.com/company/beyond-air-inc/news/beyond-air-appoints-dan-moorhead-123000082</guid>
      <pubDate>Tue, 30 Dec 2025 12:30:00 GMT</pubDate>
      <description>GARDEN CITY, N.Y., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the appointment of Dan Moorhead as Chief Financial Officer, effective January 5, 2026. Duke Dewrell, the Company&apos;s Controller, who had assumed CFO responsibilities at the Company on an interim basis in November 2025</description>
    </item>
    <item>
      <title>Beyond Air® Signs New International LungFit PH® Distribution Agreements, Most Notably in Germany and Brazil</title>
      <link>https://6ix.com/company/beyond-air-inc/news/beyond-air-signs-international-lungfit-123000032</link>
      <guid isPermaLink="true">https://6ix.com/company/beyond-air-inc/news/beyond-air-signs-international-lungfit-123000032</guid>
      <pubDate>Wed, 17 Dec 2025 12:30:00 GMT</pubDate>
      <description>Distribution network coverage expanded to a total of 39 countriesGARDEN CITY, N.Y., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the recent signing of several key international distribution agreements for LungFit® PH, expanding its network to include Germany, Brazil, Austria, th</description>
    </item>
    <item>
      <title>Beyond Air® Announces Transition of Chief Financial Officer</title>
      <link>https://6ix.com/company/beyond-air-inc/news/beyond-air-announces-transition-chief-213000327</link>
      <guid isPermaLink="true">https://6ix.com/company/beyond-air-inc/news/beyond-air-announces-transition-chief-213000327</guid>
      <pubDate>Wed, 26 Nov 2025 21:30:00 GMT</pubDate>
      <description>Launched search for permanent successorGARDEN CITY, N.Y., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Doug Larson has resigned as Chief Financial Officer to pursue another opportunity. Mr. Larson will continue to serve as CFO through December 5, 2025, at which time the CFO</description>
    </item>
    <item>
      <title>Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/beyond-air-inc/news/beyond-air-reports-fiscal-second-210500076</link>
      <guid isPermaLink="true">https://6ix.com/company/beyond-air-inc/news/beyond-air-reports-fiscal-second-210500076</guid>
      <pubDate>Mon, 10 Nov 2025 21:05:00 GMT</pubDate>
      <description>Increased revenue by 128% year over year (YoY) to $1.8 million Appointed Beyond Air Board member Bob Goodman as Interim Chief Commercial Officer Raised $12.0 million in debt financing; proforma cash, cash equivalents, restricted cash and marketable securities of $22.9 million as of September 30, 2025 Achieves certificate for Medical Device Single Audit Program (MDSAP) Updated fiscal year 2026 revenue guidance to $8 – $10 million Conference call at 4:30 p.m. ET today, November 10th GARDEN CITY, N</description>
    </item>
    <item>
      <title>Beyond Air® Secures Up to $32 Million to Accelerate Growth</title>
      <link>https://6ix.com/company/beyond-air-inc/news/beyond-air-secures-32-million-130000806</link>
      <guid isPermaLink="true">https://6ix.com/company/beyond-air-inc/news/beyond-air-secures-32-million-130000806</guid>
      <pubDate>Wed, 05 Nov 2025 13:00:00 GMT</pubDate>
      <description>Enters agreements for a $12 million promissory note and a $20 million equity line of credit with Streeterville Capital Proforma cash, cash equivalents, restricted cash and marketable securities of $22.9 million as of September 30, 2025, including $12 million from the promissory note Extends cash runway into calendar 2027 GARDEN CITY, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical com</description>
    </item>
    <item>
      <title>Beyond Air Schedules Second Fiscal Quarter 2026 Financial Results Conference Call and Webcast</title>
      <link>https://6ix.com/company/beyond-air-inc/news/beyond-air-schedules-second-fiscal-120000028</link>
      <guid isPermaLink="true">https://6ix.com/company/beyond-air-inc/news/beyond-air-schedules-second-fiscal-120000028</guid>
      <pubDate>Thu, 23 Oct 2025 12:00:00 GMT</pubDate>
      <description>GARDEN CITY, N.Y., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its second fiscal quarter ended September 30, 2025 on Monday, November 10, 2025. The Company&apos;s management team is scheduled to host a conference call and webcast at 4:30 pm</description>
    </item>
    <item>
      <title>Beyond Air to Participate in the ROTH 4th Annual Healthcare Opportunities Conference</title>
      <link>https://6ix.com/company/beyond-air-inc/news/beyond-air-participate-roth-4th-120000486</link>
      <guid isPermaLink="true">https://6ix.com/company/beyond-air-inc/news/beyond-air-participate-roth-4th-120000486</guid>
      <pubDate>Mon, 22 Sep 2025 12:00:00 GMT</pubDate>
      <description>GARDEN CITY, N.Y., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Douglas Larson, Chief Financial Officer of Beyond Air, will participate in the ROTH 4th Annual Healthcare Opportunities Conference, which is being held on Thursday, October 9, 2025, in New York, NY. Mr. Larson</description>
    </item>
    <item>
      <title>Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds</title>
      <link>https://6ix.com/company/beyond-air-inc/news/beyond-air-announces-exercise-warrants-195500926</link>
      <guid isPermaLink="true">https://6ix.com/company/beyond-air-inc/news/beyond-air-announces-exercise-warrants-195500926</guid>
      <pubDate>Mon, 08 Sep 2025 19:55:00 GMT</pubDate>
      <description>GARDEN CITY, N.Y., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding common warrants (the “Existing Warrants”) to purchase up to an aggregate of 1,439,126 shares of the Company’s common stock at</description>
    </item>
  </channel>
</rss>